MEREO BIOPHARMA GROUP PLC Finite-Lived Intangible Assets, Accumulated Amortization
MEREO BIOPHARMA GROUP PLC (MREO) had Finite-Lived Intangible Assets, Accumulated Amortization of -$396.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2024-03-27
- 2023-12-31: Finite-Lived Intangible Assets, Accumulated Amortization -$396.00K.
- 2022-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $0.00.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization |
|---|---|
| 2023-12-31 | -$396.00K 10-K · filed 2024-03-27 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |